MammaPrint

DEVICE4 trials

Sponsors

Agendia, West German Study Group, Seoul National University Hospital, Johns Hopkins University

Conditions

Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast

Phase 2

PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate

Active, not recruitingNCT03900637

Seoul National University HospitalBreast Cancer

Start: 2019-11-08End: 2028-12-31Target: 122Updated: 2024-07-31

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

CompletedNCT04129216

Johns Hopkins UniversityBreast Cancer

Start: 2019-02-20End: 2022-11-10Updated: 2024-05-07

Unknown Phase

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

CompletedNCT01617954

AgendiaHormone Receptor Positive Malignant Neoplasm of Breast

Start: 2012-05-31End: 2015-12-31Updated: 2016-01-29

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)

CompletedNCT02269813

West German Study GroupBreast Cancer

Start: 2015-04-01End: 2016-09-30Updated: 2019-08-13

Related Papers

Personalized neoadjuvant strategy in ER positive and HER2 negative breast cancer to increase BCS rate (PLATO): A prospective, multicenter, phase II clinical trial.

Journal of Clinical Oncology2024-06-012 citations

Genomic risk classification by the 70-gene signature and 21-gene assay in African American early-stage breast cancer patients.

Journal of Clinical Oncology2021-05-203 citations

Personalized neoadjuvant strategy in luminal A breast cancer to increase breast conserving surgery (BCS) rate [PLATO study].

Journal of Clinical Oncology2020-05-207 citations

Abstract P2-14-11: Treatment recommendations in ER+ patients ≤ 50 years: Comparison of the 21-gene assay and 70-gene signature in the PROMIS study

Cancer Research2020-02-15

Abstract P4-08-10: MammaPrint identifies 46% of patients, age ≤50 years with oncotype RS 18-30, as low risk and safe to forgo chemotherapy

Cancer Research2019-02-15

The 70-gene signature to provide risk stratification and treatment guidance for patients classified as intermediate by the 21-gene assay.

Journal of Clinical Oncology2016-05-204 citations

Abstract OT3-3-01: PROMIS: PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score (PROMIS)

Cancer Research2015-05-01

Abstract OT1-2-02: PROMIS: Prospective study of MammaPrint in breast cancer patients with an intermediate recurrence score (PROMIS)

Cancer Research2013-12-15